We have located links that may give you full text access.
Harnessing autophagy to overcome MEK-inhibitor induced resistance in metastatic melanoma.
British Journal of Dermatology 2018 October 20
BACKGROUND: Patients with malignant melanoma often relapse following treatment with BRAF and/or MEK inhibitors (MEKi) due to development of drug resistance by melanoma subpopulations, mediated through induction of generic survival mechanisms.
OBJECTIVES: The aim of this study was to establish the temporal pattern of CD271 regulation (a stem cell marker that mediates tumour aggressiveness) during development of resistance by melanoma to the MEKi trametinib, and to determine the association between development of resistance to trametinib and induction of pro-survival autophagy.
RESULTS: We show that CD271 and autophagic signalling are increased in human AJCC stage III primary melanomas compared to benign naevi. In vitro studies demonstrate MEKi of BRAF-mutant melanoma induced cytotoxic autophagy, followed by the emergence of CD271-expressing subpopulations. Trametinib-induced CD271 reduced autophagic flux leading to activation of pro-survival autophagy and development of MEKi-resistance. Treatment of CD271-expressing melanoma subpopulations with RNAi and small molecule inhibitors to CD271 reduced the development of MEKi-resistance, while clinically applicable autophagy modulatory agents including the cannabinoid Δ9-tetrahydrocannabinol (THC) and an inhibitor of the autophagy regulatory protein vps34 (PIK-III) reduced the survival of MEKi-resistant melanoma cells. Furthermore, combined MEK/autophagy inhibition also reduced the invasive and metastatic potential of MEKi-resistant cells in an in vivo zebrafish xenograft.
CONCLUSIONS: These results highlight a novel mechanism of MEKi-induced drug resistance and suggest that targeting autophagy may be a translatable approach to re-sensitize drug resistant melanoma cells to the cytotoxic effects of MEKi as an improved therapeutic strategy for patients with BRAF-mutant metastatic melanoma. This article is protected by copyright. All rights reserved.
OBJECTIVES: The aim of this study was to establish the temporal pattern of CD271 regulation (a stem cell marker that mediates tumour aggressiveness) during development of resistance by melanoma to the MEKi trametinib, and to determine the association between development of resistance to trametinib and induction of pro-survival autophagy.
RESULTS: We show that CD271 and autophagic signalling are increased in human AJCC stage III primary melanomas compared to benign naevi. In vitro studies demonstrate MEKi of BRAF-mutant melanoma induced cytotoxic autophagy, followed by the emergence of CD271-expressing subpopulations. Trametinib-induced CD271 reduced autophagic flux leading to activation of pro-survival autophagy and development of MEKi-resistance. Treatment of CD271-expressing melanoma subpopulations with RNAi and small molecule inhibitors to CD271 reduced the development of MEKi-resistance, while clinically applicable autophagy modulatory agents including the cannabinoid Δ9-tetrahydrocannabinol (THC) and an inhibitor of the autophagy regulatory protein vps34 (PIK-III) reduced the survival of MEKi-resistant melanoma cells. Furthermore, combined MEK/autophagy inhibition also reduced the invasive and metastatic potential of MEKi-resistant cells in an in vivo zebrafish xenograft.
CONCLUSIONS: These results highlight a novel mechanism of MEKi-induced drug resistance and suggest that targeting autophagy may be a translatable approach to re-sensitize drug resistant melanoma cells to the cytotoxic effects of MEKi as an improved therapeutic strategy for patients with BRAF-mutant metastatic melanoma. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Trending Papers
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app